Gilead Sciences (GILD): HIV Outpaces HCV Decline, PT To $95 - Wells Fargo
Tweet Send to a Friend
Wells Fargo analyst, Jim Birchenough, reiterated his Outperform rating on shares of Gilead Sciences (NASDAQ: GILD) and raised his price ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


